298 completed, 52 unknown, 23 recruiting, 15 not yet recruiting. 140 Not applicable, 87 Phase 3, 58 Phase 1, 58 Phase 2, 41 Phase 4.
Follow Hyperlipidemia: new trials by email Literature Review of Hyperlipidemia trials Research Report on Hyperlipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Coronary Artery Calcium (CAC) Testing in Primary Care Our Practice Advisory (OPA) - ASCVD, ASCVD Management | Not applicable | Not yet recruiting | Weill Medical College of Cornell University | 20 | 2027-02-01 | 2026-10-15 |
| PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD) | Not yet recruiting | Fundación Santa Fe de Bogota | 100 | 2027-02-01 | 2026-10-02 | |
| A Phase 1 Study of VELA-101 in Adult Participants VELA-101, Placebo - Healthy Participants, Hyperlipidemia | Phase 1 | Not yet recruiting | Ursa Medicines | 60 | 2026-11-01 | 2026-10-15 |
| MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Antiphospholipid (aPL)-Positive, Rheumatic Arthritis | Not yet recruiting | Axiom Bioregistry | 5000 | 2026-10-18 | 2026-10-23 | |
| A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) Enlicitide Decanoate, Placebo - Hyperlipidemia, Hypercholesterolemia | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 150 | 2026-10-15 | 2026-10-22 |
| Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors Referral to the Duke Cardiometabolic Prevention Clinic - ASCVD, Hyperlipidemia | Not applicable | Not yet recruiting | Duke University | 150 | 2026-10-02 | 2026-09-08 |
| Development and Clinical Validation of Key Technologies for Non-invasive Breath Metabolic Fingerprinting for Large-scale Population Lipid Screening Lipid Abnormality Mass Spectrometry Screening Model - Hyperlipidemia | Not yet recruiting | Beijing Anzhen Hospital | 280 | 2026-09-14 | 2026-09-10 | |
| A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia HRS-7249 Injection - Hyperlipidemia | Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 400 | 2026-09-11 | 2026-10-09 |
| Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study Pharmacist-led lipid optimization pathway - ACS (Acute Coronary Syndrome), Hyperlipidemia | Not applicable | Recruiting | University of Alberta | 2000 | 2026-08-10 | 2026-09-09 |
| Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC For Part A - Observational Cohort:, Part B: Intensive Lipid-Lowering Group, For Part B - Intensive Group - Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia | Not yet recruiting | Sun Yat-sen University | 160 | 2026-08-01 | 2026-06-29 | |
| Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals Tafolecimab - Hyperlipidemia | Not yet recruiting | Mei Gao | 60 | 2026-08-01 | 2026-07-17 | |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B) - Hyperlipidemia, Diabete Type 2 | Phase 1 | Not yet recruiting | Addpharma Inc. | 44 | 2026-07-29 | 2026-07-28 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants SAL0167 group, SAL0167 placebo group - Hyperlipidemia | Phase 1 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 120 | 2026-07-21 | 2026-07-23 |
| Regional Innovation in Chronic Disease and Elderly Care Hypertension, Cardiovascular Disease | Recruiting | Fu Jen Catholic University | 1000 | 2026-05-26 | 2026-05-28 | |
| Chronic Kidney Disease and Metabolic Disorders in the Elderly Chronic Kidney Diease, Diabetes Mellitus | Not yet recruiting | Chinese PLA General Hospital | 100000 | 2026-04-01 | 2026-03-27 | |
| New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases Interactive digital modules, Antihypertensive Medication Management - Microalbuminuria, Microalbuminuria /Creatinine Ratios ACR | Not applicable | Recruiting | New Taipei City Medical Association | 4162 | 2026-02-05 | 2026-05-14 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C Treatment A(AD-231A), Treatment B(AD-231B+AD-231C), Treatment C(AD-231A+AD-231B+AD-231C) - Hypertension, Hyperlipidemia | Phase 1 | Not yet recruiting | Addpharma Inc. | 55 | 2026-01-23 | 2025-12-31 |
| Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE), Standard Care (in control arm) - Hypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced | Phase 4 | Recruiting | Jianyin Zhou | 180 | 2026-01-18 | 2026-07-22 |
| Effect of the β-sitosterol-enriched Dietary Plan on Lipid Levels. Control group (T 1 ), Treatment Group (T 2 ) - Hyperlipidemia, Obese Individuals | Not applicable | Completed | University of Lahore | 60 | 2026-01-15 | 2026-07-10 |
| "Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Revascularization Patients Smart family doctor, Health manager, Usual Care - Hypertension, Diabete Mellitus | Not applicable | Not yet recruiting | China National Center for Cardiovascular Diseases | 951 | 2026-01-15 | 2025-12-18 |
Showing 20 of 421. Sign in to see all of them.
Hyperlipidemias (421) · Hypertension (119) · Diabetes Mellitus (80) · Obesity (46) · Cardiovascular Diseases (44) · Hypercholesterolemia (38) · Dyslipidemias (25) · Diabetes Mellitus, Type 2 (22) · Insulin Resistance (22) · Metabolic Syndrome (21) · Coronary Artery Disease (20) · HIV Infections (20) · Atherosclerosis (14) · Overweight (14) · Hyperglycemia (13)
Lipid Metabolism Disorders (420) · Nutritional and Metabolic Diseases (420) · Metabolic Diseases (418) · Dyslipidemias (396) · Vascular Diseases (148) · Glucose Metabolism Disorders (128) · Cardiovascular Diseases (126) · Endocrine System Diseases (103) · Pathological Conditions, Signs and Symptoms (77) · Signs and Symptoms (60) · Nutrition Disorders (51) · Overnutrition (51) · Body Weight (49) · Urogenital Diseases (38) · Overweight (37)
Atorvastatin (45) · Rosuvastatin Calcium (27) · Ezetimibe (20) · Simvastatin (15) · Fenofibrate (12) · evolocumab (11) · Amlodipine (9) · torcetrapib (9) · Exercise (7) · Niacin (7) · Telmisartan (7) · pitavastatin (6) · Diet (5) · Ezetimibe, Simvastatin Drug Combination (5) · Pravastatin (5)
Pfizer (14) · Amgen (10) · Merck Sharp & Dohme LLC (8) · University of Toronto (8) · AstraZeneca (7) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (6) · Yuhan Corporation (6) · HealthPartners Institute (5) · Organon and Co (5) · Brigham and Women's Hospital (4) · Chong Kun Dang Pharmaceutical (4) · Duke University (4) · Emory University (4) · Hanmi Pharmaceutical Company Limited (4)
United States (176) · China (50) · South Korea (46) · Canada (45) · Taiwan (19) · Germany (15) · Denmark (13) · France (13) · Australia (12) · Italy (12) · Netherlands (11) · Spain (11) · United Kingdom (11) · Belgium (10) · South Africa (10)
David JA Jenkins, MD, PhD, DSc (4) · Benjamin Druss, MD, MPH (2) · Christopher D Gardner (2) · David J Becker, MD (2) · Joseph P Kitzmiller, MD PhD (2) · Kyun Seop Bae, MD (2) · Lars Berglund, MD, PhD (2) · Rebecca J Brown, M.D. (2)
PMID 28304227, PMID 37994400, PMID 29685591, PMID 35277540, PMID 37658997, PMID 38018702, PMID 22301925, PMID 25091629, PMID 28324110, PMID 28487349, PMID 12221048, PMID 14519406, PMID 14552849, PMID 14728353, PMID 14728575, PMID 15464042, PMID 15505289, PMID 15534158, PMID 15791767, PMID 15802479, PMID 16186728, PMID 16310551, PMID 16522904, PMID 16837863, PMID 16919541, PMID 16940448, PMID 17011942, PMID 17101639, PMID 17387129, PMID 17387131, PMID 17407645, PMID 17521443, PMID 17998497, PMID 18018771, PMID 18038280, PMID 18068514, PMID 18078870, PMID 18167644, PMID 18172039, PMID 18332269, PMID 18398080, PMID 18468736, PMID 18519429, PMID 18559695, PMID 19029466, PMID 19029469, PMID 19095139, PMID 19104004, PMID 19328244, PMID 19407658
2005 (2), 2025 (2), K23GM100372 (2), 2014 (1), 2023 (1), K23HL090505 (1), M01RR000096 (1), M01RR000334 (1), P50MD017347 (1), R01DK055384 (1), R01DK068314 (1), R01HL057354 (1), R01HL073696 (1), R01HL079115 (1), R01HL102144 (1)